Neuroprotection: Retina's Next Frontier? - Takeaways - MDSpire

Neuroprotection: Retina's Next Frontier?

At OIS Retina in Montreal, Riad Sherif, MD, discussed Oculis’s optic neuritis program and why neuroprotection may represent the next frontier in retinal therapeutics.

  • By

  • Riad Sherif, MD

  • July 15, 2026

  • 2 min

Share

  • 1

    Riad Sherif, MD, discussed neuroprotection as a potential next frontier in retinal therapeutics at the 2026 ASRS Meeting.

  • 2

    Oculis is developing privosegtor for the restorative treatment of optic neuritis, an inflammatory condition affecting the optic nerve.

  • 3

    Optic neuritis primarily affects young adults, averaging 32 years old, with about two-thirds of patients being women.

  • 4

    The ongoing PIONEER-1 study is evaluating privosegtor, which previously showed promising results in the ACUITY trial.

  • 5

    Privosegtor improved vision by approximately 18 letters at month 3 and preserved retinal structure by maintaining GCIPL.

Original Source(s)

Neuroprotection: Retina's Next Frontier?

  • by Riad Sherif, MD

  • July 15, 2026

Related Content

Cataract Goggles Put Football Skills to the Test

Eye care teams simulate cataract vision in soccer challenge – revealing 75% drop in functional performance

  • July 14, 2026

  • 3 min
Commentary: Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities

The Economics of Home OCT

At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.